LOS ANGELES, Dec. 7, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its presentation scheduled to be delivered at the LD Micro 10th Annual Main Event Conference on Thursday, December 7, 2017 has been canceled due to severe wildfires in the Greater Los Angeles area.
The 10th Annual LD Micro Main Event Conference, previously set to be held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA, has been canceled by its organizers as a safety precaution following road closures and evacuation directives near the conference location. Consequently, CytRx's presentation will not proceed as scheduled. The conference organizers intend to reschedule for June 2018, and CytRx will provide updated presentation details when they become available.
As previously announced, CytRx plans to present at the following future investor conferences:
Biotech Showcase 2018
Tuesday, January 9, 2018 at 11:30 am PT
Hilton San Francisco Union Square, San Francisco, CA
BIO CEO & Investor Conference 2018
February 12-13, 2018 (exact date and time TBD)
New York Marriott Marquis Hotel, New York, NY
30th Annual ROTH Conference
March 11-13, 2018 (exact date and time TBD)
The Ritz Carlton, Laguna Niguel, CA
Presentation dates and times, along with any links to potential webcasts, will be provided closer to the actual events.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. CytRx is also rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies. Aldoxorubicin, CytRx's most advanced drug conjugate, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to NantCell, Inc.
This press release contains forward-looking statements. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties relating to plans for regaining compliance with the Nasdaq rules and higher share price of our common stock; the ability of NantCell, Inc., to obtain regulatory approval for its products that use aldoxorubicin; the ability of NantCell, Inc., to manufacture and commercialize products or therapies that use aldoxorubicin; the amount, if any, of future milestone and royalty payments that we may receive from NantCell, Inc.; our ability to develop new ultra-high potency drug candidates based on our LADRTM technology platform; and other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
SOURCE CytRx Corporation